Gradientech announces Notice of Allowance from Chinese Patent Office

Uppsala, March 20, 2079. Gradientech AB, a Swedish biotech and diagnostic company developing the next generation ultra-rapid antibiotic susceptibility testing (AST) system for appropriate treatment of sepsis, today announces that the Company has received a Notice of Allowance from the Chinese Patent Office (CHN) for the patent application no. 201480038696, "New Use of a Fluidic Device".

The patent application covers the proprietary minimum inhibitory concentration (MIC) determination of a bacterial sample within a microfluidic controlled environment that is part of the technology platform of the Company’s diagnostic system QuickMIC™ for ultra-rapid AST. A Notice of Allowance signifies that Gradientech will be entitled to receive patent protection until 2034 in China for the allowed claims when the patent is issued. Gradientech has already been granted patent protection for MIC determination in Europe and Japan.

For further information, please contact:
Sara Thorslund, PhD, CEO Gradientech
Tel: +46 736 29 35 80

Gradientech is an ISO13485 certified company since 2017


Gradientech AB
Uppsala Science Park
SE-751 83 Uppsala


About Gradientech

Gradientech develops, manufactures and sells innovative microfluidic products for high-quality analysis of the behavior of cells and organisms in response to gradients of biomolecules. Our aim is to pioneer life science and healthcare.

Copyright © 2024 Gradientech. All rights reserved. Gradientech, QuickMIC and CellDirector are registered trademarks or trademarks of Gradientech AB.

Next-generation antimicrobial susceptibility testing

Take a look at our E-book